The site you are about to enter is intended for US
healthcare providers only
.
Please confirm that you are a US healthcare provider.
You are now leaving ZULRESSO.com,
the official site for ZULRESSO® (brexanolone)
.
This link will take you to another Sage Therapeutics, Inc. website.
You are now leaving Zulresso.com,
the official site for ZULRESSO® (brexanolone) and entering one that is not
owned or controlled by Sage Therapeutics, Inc.
.
Sage Therapeutics, Inc. makes no representation as to the information contained on sites we do not own or control. Sage Therapeutics, Inc. does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
As of January 1, 2025, ZULRESSO® (brexanolone)
is no longer commercially available in the U.S.
Please contact us at Sage Central® Patient Support at 1-844-472-4379
if you have any questions or need more information
Resources & Support
Financial assistance programs from Sage Central*
We understand cost may be a concern to many patients. Learn more about available financial assistance programs.
*Restrictions may apply. Patients with insurance provided under Medicare, Medicaid, or any other federal or state healthcare program are not eligible for financial assistance.
Eligible commercially insured patients may pay as little as $0*
Concerns about the cost of ZULRESSO® (brexanolone) should not prevent you from seeking the treatment your healthcare provider has prescribed. Sage Central offers several financial assistance programs that can help reduce out-of-pocket costs related to your treatment.
Once you’ve enrolled with Sage Central, you will automatically have access to the financial assistance programs for which you may be eligible. Your continued eligibility is subject to your satisfaction of the terms and conditions of the financial assistance programs.
The ZULRESSO Drug Copay Assistance Program
This program is designed to help reduce eligible out-of-pocket copay costs related to the drug. If you have commercial insurance, you may be eligible for copay assistance to reduce your out-of-pocket, drug-related copay costs up to $15,000—regardless of income level* and subject to certain terms and conditions.
The ZULRESSO Infusion Copay Assistance Program
This program is designed to help reduce eligible out-of-pocket copay costs related to the administration of ZULRESSO, which is the 2.5-day infusion. If you have commercial insurance, you may be eligible for copay assistance to reduce your out-of-pocket, infusion-related copay costs up to $2,000—regardless of income level† and subject to certain terms and conditions.
(Residents of Massachusetts and Rhode Island are not eligible for infusion assistance.)
Free Drug Program
This program provides ZULRESSO at no cost for eligible patients who meet certain income criteria and would not otherwise have access to ZULRESSO. If you are uninsured or underinsured and meet our financial eligibility criteria, you may qualify for the Free Drug Program. Subject to terms and conditions and eligibility criteria.‡
The Treating Center you and your healthcare provider choose for your infusion of ZULRESSO will be required to provide an attestation that it will not bill you or your insurer for any costs associated with ZULRESSO.
*ZULRESSO DRUG COPAY ASSISTANCE PROGRAM TERMS AND CONDITIONS
The ZULRESSO Drug Copay Assistance Program (the “Drug Copay Program”) helps eligible patients with private, commercial health insurance pay for a patient’s out-of-pocket costs associated with the drug up to a maximum of $15,000. Cash-paying patients and patients eligible for a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”), are not eligible to participate in the Drug Copay Program. Sage Therapeutics, Inc., may rescind, revoke, or amend the Drug Copay Program at any time. For full patient eligibility requirements and program terms and conditions, visit SageCentralSupport.com.
†ZULRESSO INFUSION COPAY ASSISTANCE PROGRAM TERMS AND CONDITIONS
The ZULRESSO Infusion Copay Assistance Program (the “Infusion Copay Program”) helps eligible patients with private, commercial health insurance pay for a patient’s out-of-pocket, infusion-related costs associated with ZULRESSO up to a maximum of $2,000. Cash-paying patients and patients eligible for a state or federally funded insurance program, including but not limited to Medicare, Medicaid. TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”), are not eligible to participate in the Infusion Copay Program. Residents of Massachusetts and Rhode Island are not eligible to participate in the Infusion Copay Program. Sage Therapeutics, Inc., may rescind, revoke, or amend the Infusion Copay Program at any time. For full patient eligibility requirements and program terms and conditions, visit SageCentralSupport.com.
‡FREE DRUG PROGRAM TERMS AND CONDITIONS
To be eligible to participate in the ZULRESSO® Free Drug Program (the “FDP”), the patient must: (i) Be prescribed ZULRESSO® for an on-label diagnosis; (ii) Have household income less than or equal to 500% of the Federal Poverty Level (FPL); (iii) Be uninsured or rendered uninsured under any of the following circumstances: (a) Patient has no healthcare insurance, (b) Patient is insured but such insurance does not cover ZULRESSO, or (c) Patient is insured with coverage for ZULRESSO, but is ineligible for the ZULRESSO Copay Assistance Program, and cannot afford the medication (patient out-of-pocket costs are greater than $25); (iv) Reside in the United States or a U.S. territory; (v) Be treated by a healthcare professional in the United States or a U.S. Territory; and (vi) Be 15 years of age or older. Patients enrolled in Medicare, Medicaid or any other federal or state funded health plan may participate in the FDP if they receive the free product outside of their government-funded benefits. The treating healthcare provider must certify that based on his/her independent medical judgment, ZULRESSO is a medically appropriate treatment for the patient. The healthcare provider must certify not to bill the patient or the patient’s insurer for the cost of ZULRESSO. If the patient is enrolled in any federal or state funded health plans, the healthcare provider must not bill any costs associated with ZULRESSO and corresponding treatment costs within a Diagnostic Related Group (DRG). The patient will be informed that she must not (i) seek reimbursement for the free drug from their health plan, and (ii) count the cost of the free drug towards her out-of-pocket spending requirements, if any, under her insurance. The free drug provided under the FDP is not conditioned on any past or future purchases. For any patient enrolled in a readily identifiable Medicare, Medicaid or other government funded plan, Sage will send a letter to the plan informing it that: (i) the patient is receiving free product from the ZULRESSO FDP outside of the patient’s Medicare/Medicaid plan benefit, (ii) the patient and her physician have been informed that they must not seek reimbursement for the free drug from their health plan or count the cost of the free product towards the patient’s out-of-pocket spending requirements, and (iii) the plan should discontinue any pending prior authorization or coverage appeal associated with the patient.